We also suggest that therapeutic combinations involving an HSP110 inhibitor could be envisioned as a treatment for poorly understood lymphomas that share some similar molecular features with cHL and PMBL, such as gray zone intermediate lymphoma (MGZL) [58, 59]. The gene discussed is HSPH1; the disease is lymphoma.